{"id":400222,"date":"2020-12-15T11:48:09","date_gmt":"2020-12-15T16:48:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400222"},"modified":"2020-12-15T11:48:09","modified_gmt":"2020-12-15T16:48:09","slug":"telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/","title":{"rendered":"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d"},"content":{"rendered":"

<\/p>\n

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d<\/i><\/b><\/p>\n

The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers.<\/i><\/b><\/p>\n

MELBOURNE, Australia & PARIS & BOSTON–(BUSINESS WIRE<\/a>)–
\nRegulatory News:\n<\/p>\n

Telix Pharmaceuticals Limited (ASX: TLX, \u2018Telix\u2019) <\/b>abiopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna Kea Technologies<\/b> (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, \u2018Mauna Kea\u2019)<\/b> inventor of Cellvizio\u00ae, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE\/nCLE) platform, today announced an exclusive scientific and clinical research collaboration in the field of molecular imaging guided urologic oncology.\n<\/p>\n

\nThe Telix and Mauna Kea scientific and clinical research collaboration is called the \u201cImaging and Robotics in Surgery (IRiS) Alliance,\u201d or \u201cIRiS Alliance,\u201d and was created to further develop the combined technological capabilities of both companies. The IRiS Alliance was formed based on the belief that the use of cancer-specific Positron Emission Tomography (PET) imaging agents, including dual-modality tracers that combine PET and fluorescent (optical) techniques, in conjunction with confocal laser endomicroscopy, may significantly improve surgical techniques and clinical outcomes in patients with urologic cancers.\n<\/p>\n

\nThe IRiS Alliance aims to demonstrate that pre-operative planning, intra-operative guidance, surgical margin assessment and other surgical parameters may be improved by combining these modalities. The initial focus of the IRiS Alliance is to develop and evaluate the use of Telix\u2019s dual-modality PET and optical imaging tracers, together with Mauna Kea\u2019s unique near-infrared version of the Cellvizio endomicroscopy platform to facilitate fluorescence-guided surgical interventions for prostate and kidney cancers.\n<\/p>\n

\n\u201cWe are excited to announce this exclusive scientific and clinical research collaboration with Telix in the field of urologic oncology,\u201d said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. \u201cThe IRiS Alliance endeavors to combine the strengths of Telix\u2019s molecular targeting, together with Cellvizio\u2019s real-time in vivo cellular imaging, to bring dual modality molecular imaging to the operating theatre for the first time. The IRiS Alliance aims to significantly transform how the urologic surgeon will evaluate, target, excise, and confirm surgical margins at the cellular level. Our collaboration will further empower surgeons to fight cancers and save lives. We expect to begin pre-clinical and clinical feasibility studies in 2021.\u201d\n<\/p>\n

\n\u201cThe cutting-edge techniques our respective companies have developed in molecular targeting and real-time in vivo cellular imaging have a natural synergy and we are extremely pleased to have formalized this ground-breaking partnership,\u201d said Christian Behrenbruch, Chief Executive Officer and Managing Director of Telix Pharmaceuticals Limited. \u201cThrough the IRiS Alliance, Telix and Mauna Kea together aim to deliver quantum improvements in surgical techniques and clinical outcomes in patients with urologic cancers, starting with prostate and kidney cancers, with the ultimate objective of improving the lives of the patients we serve.\u201d\n<\/p>\n

About Telix Pharmaceuticals Limited <\/b><\/p>\n

\nTelix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in prostate, renal and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com<\/a><\/p>\n

About Mauna Kea Technologies<\/b><\/p>\n

\nMauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company\u2019s flagship product, Cellvizio\u00ae, has received clearance\/approval in a wide range of applications in more than 40 countries, including the United States, Europe, Japan, and China. For more information on Mauna Kea Technologies, visit www.maunakeatech.com<\/a><\/p>\n

Disclaimers<\/b><\/p>\n

Telix Pharmaceuticals Limited
\n
<\/b>This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the \u201cU.S. Securities Act\u201d), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction.\n<\/p>\n

Mauna Kea Technologies
\n
<\/b>This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorit\u00e9 des march\u00e9s financiers (AMF)) on August 7, 2020 under number 926346434_20200807 and available on the Company’s website (www.maunakeatech.com<\/a>), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201215005893\/en\/<\/a><\/span><\/p>\n

Mauna Kea Technologies
\n<\/span>
<\/b>United States
\n<\/span><\/b>
Mike Piccinino, CFA
\n
Westwicke, an ICR Company
\n
443-213-0500<\/p>\n

France and Europe
\n<\/span><\/b>
NewCap – Investor Relations
\n
Thomas Grojean
\n
+33 (0)1 44 71 94 94
\n
maunakea@newcap.eu<\/a><\/p>\n

Telix Corporate Contact
\n<\/span><\/b>
Dr. Christian Behrenbruch
\n
Telix Pharmaceuticals Limited
\n
CEO
\n
chris@telixpharma.com<\/a><\/p>\n

Telix Investor Relations
\n<\/span><\/b>
Dr. David N. Cade
\n
Telix Pharmaceuticals Limited
\n
CBO & Head of Investor Relations
\n
david.cade@telixpharma.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts Australia\/Oceania United States France North America Australia Europe<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Surgery Oncology Health Genetics Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers. MELBOURNE, Australia & PARIS & BOSTON–(BUSINESS WIRE)– Regulatory News: Telix Pharmaceuticals Limited (ASX: TLX, \u2018Telix\u2019) abiopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, \u2018Mauna Kea\u2019) inventor of Cellvizio\u00ae, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE\/nCLE) platform, today announced an exclusive scientific and clinical research collaboration in the field of molecular imaging guided urologic oncology. The Telix and Mauna Kea scientific … <\/p>\n

Continue reading “Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400222","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTelix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers. MELBOURNE, Australia & PARIS & BOSTON–(BUSINESS WIRE)– Regulatory News: Telix Pharmaceuticals Limited (ASX: TLX, \u2018Telix\u2019) abiopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, \u2018Mauna Kea\u2019) inventor of Cellvizio\u00ae, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE\/nCLE) platform, today announced an exclusive scientific and clinical research collaboration in the field of molecular imaging guided urologic oncology. The Telix and Mauna Kea scientific … Continue reading "Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T16:48:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d\",\"datePublished\":\"2020-12-15T16:48:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/\"},\"wordCount\":1097,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/\",\"name\":\"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-12-15T16:48:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/","og_locale":"en_US","og_type":"article","og_title":"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d - Market Newsdesk","og_description":"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d The IRiS Alliance is an exclusive scientific and clinical research collaboration that combines two highly complementary technologies to deliver greater precision in the diagnosis and surgical management of urological cancers. MELBOURNE, Australia & PARIS & BOSTON–(BUSINESS WIRE)– Regulatory News: Telix Pharmaceuticals Limited (ASX: TLX, \u2018Telix\u2019) abiopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) and Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA, \u2018Mauna Kea\u2019) inventor of Cellvizio\u00ae, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE\/nCLE) platform, today announced an exclusive scientific and clinical research collaboration in the field of molecular imaging guided urologic oncology. The Telix and Mauna Kea scientific … Continue reading \"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T16:48:09+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d","datePublished":"2020-12-15T16:48:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/"},"wordCount":1097,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/","name":"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-12-15T16:48:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201215005893r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-and-mauna-kea-technologies-announce-the-imaging-and-robotics-in-surgery-iris-alliance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the \u201cImaging and Robotics in Surgery (IRiS) Alliance\u201d"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400222","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400222"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400222\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400222"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400222"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400222"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}